Definitive Contract 75A50122C00080
Award Date
9/27/22
Potential Completion Date
9/22/32
Potential Value
$319M
Awardee
Venatorx Pharmaceuticals Inc.
Ultimate Awardee
Not listed
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Malvern, PA 19355, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
3
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Defense Threat Reduction Agency awarded a $19,969,099.47 cost-plus-fixed-fee definitive contract to Venatorx Pharmaceuticals Inc. (doing business as Venatorx) for the research, development, and manufacturing of penicillin binding proteins. The contract does not have a set-aside designation and has a completion date of October 27, 2023. Venatorx, a for-profit organization, has a history of receiving federal contracts and grants from agencies such as the Department of Health and Human Services...
This is a $44,503,613.75 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Venatorx Pharmaceuticals Inc. to advance the development of a novel beta-lactamase inhibitor targeting multidrug-resistant Acinetobacter baumannii. The contract supports research and development of non-beta-lactam inhibitors of penicillin binding proteins to address this public health threat. The award has no set-aside designation, indicating full and open...
<p>This is a $323,554,976.00 Firm Fixed Price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Paratek Pharmaceuticals, Inc. for the development of an antibiotic to treat a biothreat indication. The contract has an ultimate completion date of December 17, 2029 and was awarded on December 18, 2019. This contract is not associated with a set-aside program.</p>
This is a definitive cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Basilea Pharmaceutica International Ltd, a biopharmaceutical company based in Switzerland. The $85,175,444 contract supports the clinical development of BAL30072, a novel monosulfactam antibiotic for treating infections caused by multidrug-resistant gram-negative bacterial pathogens. This contract is not set aside...
This is a federal contract award to Regeneron Pharmaceuticals Inc., a for-profit manufacturer of pharmaceuticals and therapeutics. The $692,086,314.00 award was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS). The contract is for the development and production of "novel antibodies against influenza virus, emerging, re-emerging, and pre-emerging pathogens" under an Other...
This is a $49,795,199.00 cost-sharing definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Spero Therapeutics, Inc. for the development of SPR994, an oral carbapenem antibiotic for the treatment of drug-resistant Gram-negative bacterial infections. The contract was awarded on July 12, 2018 with a period of performance through October 31, 2026. It was not set aside for any specific business category. The contract originated from a Broad...
This federal contract award to Eitr Biologics, Inc. for $499,896.06 was issued by the Defense Health Agency (DHA) on July 1, 2024. The award is for the development of a novel therapeutic medical countermeasure capable of protecting against pneumonic unencapsulated Yersinia pestis, the causative agent of pneumonic plague. The contract is a Firm Fixed Price Delivery Order with a completion date of June 30, 2025. This award is part of a larger Indefinite Delivery Vehicle (IDV) held by Eitr...
This is a $267,582,260 definitive cost-sharing contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Basilea Pharmaceutica International Ltd, Allschwil, doing business as Basilea Pharmaceutica International SA, Allschwil. The contract supports the development of antimicrobials for the treatment of resistant fungal and bacterial infections, targeting high-priority pathogens such as carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and...
The U.S. Department of Health and Human Services (HHS), through the Office of the Assistant Secretary for Preparedness and Response (ASPR), has awarded a $748,039 firm fixed-price definitive contract to Partner Therapeutics, Inc., a biopharmaceutical company based in Lexington, Massachusetts. The contract is for research and development to repurpose the host-directed therapy FX06 for the treatment of severe disease in patients with Sudan Virus Disease (SVD) or other filoviruses. This contract is...
This federal contract award, valued at up to $114,146,088.00, was issued by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Vedanta Biosciences, Inc., a biotechnology company. The contract was awarded under a Broad Agency Announcement (BAA) solicitation from BARDA (Biomedical Advanced Research and Development Authority) that sought proposals for the advanced research and development of medical countermeasures against...